News & Events
Contact
Home
Company
History and Mission
Team
Careers
Research
Technology
Products
Clinical trials
For patients
Partnering
News & Events
Contact
Datenschutz
Search
Search
Recent Posts
€ 38.7 Mio. German government funding for the clinical development of a Corona medication
CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant
CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment
TV report on COR-101
Recent Comments
No comments to show.
